Retatrutide· 30mg
GIP/GLP-1/Glucagon triple agonist
Vendor VerdictScore
Our Rating — VialVerdict's internal supplier score until more customer reviews are available.
Product + vendor context
Retatrutide from Peptide Society
This page covers Retatrutide as sold by Peptide Society. Product-specific reviews are only counted when a reviewer selects this exact vendor/product pair. Vendor reviews, external review signals, and the vendor VerdictScore are shown separately so broad vendor reputation does not masquerade as product-specific proof.
Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. It is not an FDA-approved medication, but it attracts heavy research and buyer interest because early clinical studies reported very large body-weight reductions compared with older incretin therapies.
Current catalogue snapshot: 30mg vial, $99.99 total, $3.33/mg, listed in stock. VialVerdict does not yet have a published purity value for this row; confirm the latest COA before ordering.
Frequently asked questions about Peptide Society Retatrutide
Is Peptide Society Retatrutide reviewed separately from vendor reviews?
What does VialVerdict know about this Retatrutide listing?
Why show vendor reviews on a Retatrutide product page?
Does VialVerdict earn from Peptide Society links?
Vendor-level reviews for Peptide Society
These reviews describe the vendor overall — shipping, packaging, support, and fulfilment — not necessarily this exact Retatrutide listing.
Other vendors selling Retatrutide
Ranked by rating, price, and listed product data.